The Mallinckrodt 2021
Advancing ECP Immunomodulation Investigator Award:
Refining THERAKOS ECP Immunomodulation™
Frequently Asked Questions
Who is eligible for the grant award? Are applicants from all countries eligible?
Clinicians, physicians, scientists or others who are interested in ECP Immunomodulation based in the EMEA region* are encouraged to apply.
How much funding is available?
One educational grant of €50,000 will be awarded to a single institution to be used in a specified time frame of 12 months.
Is the grant awarded to the applicant’s institution?
Yes, this award is designed to go to an institution.
Who is on the Investigator Award Committee?
The Investigator Award Committee will consist of Medical Scientists employed by Mallinckrodt Pharmaceuticals. The Award Committee will score applications based on the criteria outlined in the submission form – specifically on scientific merit, its novelty and feasibility – to select a winner as well as a runner-up.
Once a grant is awarded, will there be any requirements for the investigator to meet certain milestones or report to Mallinckrodt Pharmaceuticals?
Yes, the awardee is required to share the outcomes of the research through a report at the completion of the project, the exact details on reporting and potential publications will be defined in a contract agreement.
What can I do if my project does not fit the above-mentioned criteria or gets rejected?
If case your project does not fit the above-mentioned criteria or has been rejected you can still apply for an investigator initiated research program following the link at: https://investigator-initiated-research.mnk.com.
*Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Egypt, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Jordan, Netherlands, Norway, Poland, Portugal, Saudi Arabia, Slovenia, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, United Kingdom.